Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02291913
Title Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC

Her2-receptor negative breast cancer


Everolimus + Tamoxifen

Anastrozole + Everolimus

Everolimus + Fulvestrant

Everolimus + Letrozole

Everolimus + Toremifene

Everolimus + Exemestane

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.